Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Allakos Faces Strategic Uncertainty Following AK006 Phase 1 Trial Failure and Workforce Reduction
Allakos Cuts 75% of Workforce After Chronic Hives Trial Failure
Institutional Owners May Consider Drastic Measures as Allakos Inc.'s (NASDAQ:ALLK) Recent US$55m Drop Adds to Long-term Losses
Hold Rating on Allakos Amid Clinical and Financial Setbacks With AK006
12 Health Care Stocks Moving In Monday's Pre-Market Session
Akero AKRO Phase 2b Success; Allakos ALLK Strategic Alternatives
Why Is Allakos Stock Plunging On Monday?
Top Midday Decliners
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)
Dow Edges Higher; AT&T Posts Upbeat Earnings
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure
Allakos Downgraded to Neutral From Overweight at Piper Sandler
Hold Rating Maintained for Allakos Amid AK006 Program Discontinuation and Strategic Uncertainty
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December
JMP Securities Downgrades Allakos(ALLK.US) to Hold Rating
Sector Update: Health Care Stocks Mixed Premarket Monday
Allakos ALLK Phase 1 Discontinuation; Akero AKRO Phase 2b Data
Allakos Plunges 75% on Phase 1 Data for Urticaria Asset